Costs associated with unplanned readmissions among patients with heart failure with and without hyponatremia
- PMID: 31361839
- DOI: 10.1093/ajhp/zxy064
Costs associated with unplanned readmissions among patients with heart failure with and without hyponatremia
Abstract
Purpose: Costs associated with unplanned readmissions among patients with heart failure with and without hyponatremia were studied.
Methods: This study estimated the costs of patients hospitalized for heart failure (HF) discharged with or without corrected sodium. A model was developed to monetize the 30-day readmission risk based on hyponatremia correction. Costs of discharging patient with corrected versus uncorrected hyponatremia were estimated using readmission rates from a previously published study and hospitalization costs from the Healthcare Costs and Utilization Cost Project and the Premier Healthcare Database.
Results: Discharging patients with HF and hyponatremia increased costs from $488-$569 per discharge compared to patients with corrected hyponatremia. This range reflected differences in readmission rates and sources of hospitalization costs. Sensitivity analyses showed hospitalization costs and readmission rates had the largest impact on model results.
Conclusion: A retrospective study supports the value of upfront monitoring and correction of low serum sodium levels before discharge among patients with HF and hyponatremia by presenting an economic argument in addition to the clinical rational for reducing risk of readmission.
Keywords: heart failure; hospital costs; hyponatremia; readmission.
© American Society of Health-System Pharmacists 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Comment on
-
Impact of Hyponatremia Correction on the Risk for 30-Day Readmission and Death in Patients with Congestive Heart Failure.Am J Med. 2016 Aug;129(8):836-42. doi: 10.1016/j.amjmed.2016.02.036. Epub 2016 Mar 24. Am J Med. 2016. PMID: 27019042
Similar articles
-
Impact of Hyponatremia Correction on the Risk for 30-Day Readmission and Death in Patients with Congestive Heart Failure.Am J Med. 2016 Aug;129(8):836-42. doi: 10.1016/j.amjmed.2016.02.036. Epub 2016 Mar 24. Am J Med. 2016. PMID: 27019042
-
Healthcare resource burden associated with hyponatremia among patients hospitalized for heart failure in the US.J Med Econ. 2013;16(3):415-20. doi: 10.3111/13696998.2013.766615. Epub 2013 Jan 23. J Med Econ. 2013. PMID: 23336297
-
Utilization and budget impact of tolvaptan in the inpatient setting among patients with heart failure and hyponatremia.Curr Med Res Opin. 2018 Mar;34(3):559-566. doi: 10.1080/03007995.2018.1423958. Epub 2018 Jan 22. Curr Med Res Opin. 2018. PMID: 29297709
-
The effect of nurse-led education on hospitalisation, readmission, quality of life and cost in adults with heart failure. A systematic review.Patient Educ Couns. 2018 Mar;101(3):363-374. doi: 10.1016/j.pec.2017.10.002. Epub 2017 Oct 5. Patient Educ Couns. 2018. PMID: 29102442
-
Hyponatremia in Patients with Heart Failure beyond the Neurohormonal Activation Associated with Reduced Cardiac Output: A Holistic Approach.Cardiology. 2022;147(5-6):507-520. doi: 10.1159/000526912. Epub 2022 Sep 21. Cardiology. 2022. PMID: 36130527 Review.
Cited by
-
Systematic Review and Meta-Analysis of the Financial Impact of 30-Day Readmissions for Selected Medical Conditions: A Focus on Hospital Quality Performance.Healthcare (Basel). 2024 Mar 29;12(7):750. doi: 10.3390/healthcare12070750. Healthcare (Basel). 2024. PMID: 38610171 Free PMC article. Review.
-
A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014-2020).Pharmacoeconomics. 2020 Nov;38(11):1219-1236. doi: 10.1007/s40273-020-00952-0. Pharmacoeconomics. 2020. PMID: 32812149 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous